<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27635733</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>11</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2044-5385</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>09</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Blood cancer journal</Title>
                <ISOAbbreviation>Blood Cancer J</ISOAbbreviation>
            </Journal>
            <ArticleTitle>MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e470</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/bcj.2016.79</ELocationID>
            <Abstract>
                <AbstractText>Although imatinib is highly effective in the treatment of chronic myeloid leukemia (CML), 25-30% patients do not respond or relapse after initial response. Imatinib uptake into targeted cells is crucial for its molecular response and clinical effectiveness. The organic cation transporter 1 (OCT1) has been proposed to be responsible for this process, but its relevance has been discussed controversially in recent times. Here we found that the multidrug and toxin extrusion protein 1 (MATE1) transports imatinib with a manifold higher affinity. MATE1 mainly mediates the cellular uptake of imatinib into targeted cells and thereby controls the intracellular effectiveness of imatinib. Importantly, MATE1 but not OCT1 expression is reduced in total bone marrow cells of imatinib-non-responding CML patients compared with imatinib-responding patients, indicating that MATE1 but not OCT1 determines the therapeutic success of imatinib. We thus propose that imatinib non-responders could be identified early before starting therapy by measuring MATE1 expression levels.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Harrach</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmidt-Lauber</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Experimental Nephrology, Medizinische Klinik D, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pap</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pavenstädt</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Nephrology, Department of Internal Medicine D, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schlatter</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Experimental Nephrology, Medizinische Klinik D, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schmidt</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine A, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Berdel</LastName>
                    <ForeName>W E</ForeName>
                    <Initials>WE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine A, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schulze</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Molecular Nephrology, Department of Internal Medicine D, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Edemir</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinic and Polyclinic of Internal Medicine IV, Hematology and Oncology, University Hospital Halle, Halle (Saale), Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeromin</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>MLL Munich Leukemia Laboratory, München, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haferlach</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>MLL Munich Leukemia Laboratory, München, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ciarimboli</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Experimental Nephrology, Medizinische Klinik D, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bertrand</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>Department of Orthopedic Surgery, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>09</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Blood Cancer J</MedlineTA>
            <NlmUniqueID>101568469</NlmUniqueID>
            <ISSNLinking>2044-5385</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C521869">MATE1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D027701">Organic Cation Transport Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D027702">Organic Cation Transporter 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8A1O1M485B</RegistryNumber>
                <NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.2</RegistryNumber>
                <NameOfSubstance UI="D016044">Fusion Proteins, bcr-abl</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D016044" MajorTopicYN="N">Fusion Proteins, bcr-abl</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015464" MajorTopicYN="N">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D027701" MajorTopicYN="N">Organic Cation Transport Proteins</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D027702" MajorTopicYN="N">Organic Cation Transporter 1</DescriptorName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <CoiStatement>TH partly owns MLL Munich Leukemia Laboratory. SJ is employed by MLL Munich Leukemia Laboratory. The other authors declare no conflict of interest and nothing to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>08</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>9</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>11</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27635733</ArticleId>
            <ArticleId IdType="pii">bcj201679</ArticleId>
            <ArticleId IdType="doi">10.1038/bcj.2016.79</ArticleId>
            <ArticleId IdType="pmc">PMC5056971</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Am J Physiol Renal Physiol. 2009 Jun;296(6):F1504-13</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19357179</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2004 Apr;53(4):313-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14658008</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>N Engl J Med. 2010 Jun 17;362(24):2251-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20525993</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2010 Mar;9(3):215-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20190787</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Med Chem. 2013 Feb 14;56(3):781-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23241029</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leukemia. 2010 Apr;24(4):765-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20147974</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Xenobiotica. 2007 Jun;37(6):618-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17614008</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2007 Dec 1;110(12):4064-72</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17761829</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2014 Feb 27;123(9):1427-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24578499</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2011 Mar;10(3):531-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21252289</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2013 Jan 24;121(4):628-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23223357</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharm Res. 2007 Jul;24(7):1227-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17473959</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Neuropharmacology. 2006 Jun;50(8):941-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16581093</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2010 Apr;333(1):341-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20065018</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leukemia. 2015 Sep;29(9):1823-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26088952</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(12):e52247</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23284953</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Leukemia. 2015 May;29(5):1123-32</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25676422</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2008 May 15;14(10):3141-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18483382</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Pharmacol. 2002 Jul;136(6):829-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12110607</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2002 Mar 15;99(6):1928-37</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11877262</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2014 Jan 23;123(4):494-500</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24311723</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2013 Aug 8;122(6):872-84</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23803709</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Pharmacol. 2005 Apr;67(4):1067-77</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15630081</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jun 1;28(16):2761-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20421539</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Treat Rev. 2009 Dec;35(8):692-706</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19733976</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 2001 Aug 3;293(5531):876-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11423618</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2014 Feb 15;20(4):985-94</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24352644</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 1976 Oct 15;18(4):421-31</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">789258</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacogenomics J. 2009 Apr;9(2):127-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19172157</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2005 Oct 1;106(7):2520-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15956284</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Pharmacol Exp Ther. 2008 Feb;324(2):558-67</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18042828</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2013 Jun 13;121(24):4965-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23766461</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>